骨髓增生异常综合征(MDS)是一种起源于造血干细胞的克隆性疾病,疾病临床表现呈异质性,多数患者最终转化为急性髓细胞性白血病。近年来发现DNA甲基化异常与MDS的严重程度及预后有关,去甲基化治疗作为一种新的方法引入到MDS的治疗中。现将指导MDS患者临床合理使用去甲基化药物的生物学指标进行综述。 Myelodysplastic syndrome (MDS) is a clonal disease stemming from hematopoietic stem cells. The clinical manifestations of the disease are heterogeneous, and most patients eventually become acute myeloid leukemias. In recent years, abnormal DNA methylation was found to be associated with the severity and prognosis of MDS. As a new method, demethylation therapy was introduced into the treatment of MDS. The MDS patients will now guide the clinical rational use of demethylation drugs biological indicators are reviewed.